TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06377514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test IOL Model DEN00V
Description: Eligible subjects will be randomized in a 1:1 ratio to receive the Test IOL Model DEN00V in both eyes for the duration of the study
Study: NCT05600790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress
Description: Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study: NCT03994497

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
Study: NCT06377514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control IOL Model DCB00
Description: Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model DCB00 in both eyes for the duration of the study
Study: NCT06280547

Intervention type: OTHER
Intervention: Oral health education
Description: Oral Health Education Program performed in the school.
Study: NCT06145386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Strength Training
Description: Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Strength Training
Description: Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19
Study: NCT05110716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bundle-size 1
Description: In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bundle-size 1
Description: In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
Study: NCT05644353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC.
Study: NCT05986097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: We will provide participants recipes and information to support this dietary change.
Study: NCT06283394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storefront Choice Architecture
Description: An Instacart storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storefront Choice Architecture
Description: An Instacart storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh Funds
Description: The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh Funds
Description: The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh Funds
Description: The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh Funds
Description: The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Framing
Description: They will receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following end of the month).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Framing
Description: They will receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following end of the month).
Study: NCT05968989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUMOS0116-00-VP( FLUMos-v2)
Description: The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUMOS0116-00-VP( FLUMos-v2)
Description: The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUMOS0116-00-VP( FLUMos-v2)
Description: The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013
Study: NCT05903456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE（transcatheter arterial chemoembolization）
Description: TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin soft capsules
Description: Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
Study: NCT05596474

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet-root juice
Description: Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Beet-root juice
Description: Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: red-light therapy
Description: Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: red-light therapy
Description: Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: sham light
Description: Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sham light
Description: Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
Study: NCT04312789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Given PO
Study: NCT05412667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TWK10
Description: 1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection.
Study: NCT06507137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fractal
Description: Walking in a treadmill while synchronizing their steps with fractal external visual cues

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isochronous
Description: Walking in a treadmill while synchronizing their steps with isochronous external visual cues
Study: NCT05532124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAENNEC (Human Placenta Hydrolysate)
Description: Intravenous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAENNEC (Human Placenta Hydrolysate)
Description: Intravenous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAENNEC (Human Placenta Hydrolysate)
Description: Intravenous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAENNEC (Human Placenta Hydrolysate)
Description: Intravenous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAENNEC (Human Placenta Hydrolysate)
Description: Intravenous Injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Intravenous Injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Intravenous Injection
Study: NCT06507137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Walking in a treadmill
Study: NCT05801172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen plus infiltration anesthesia with lidocaine for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen plus infiltration anesthesia with lidocaine for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen plus paracervical block anesthesia with lidocaine for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in paracervical block at the start of the procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen plus paracervical block anesthesia with lidocaine for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in paracervical block at the start of the procedure
Study: NCT04994522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Three 40 mg tablets given as a single oral 120 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Three 40 mg tablets given as a single oral 120 mg dose.
Study: NCT05341193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
Description: Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
Description: Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy.
Study: NCT05154578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 Vaccine
Description: 0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 Vaccine
Description: 0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.
Study: NCT05545371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunization procedures
Description: The subjects were vaccinated with rabies vaccine according to different immunization procedures

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunization procedures
Description: The subjects were vaccinated with rabies vaccine according to different immunization procedures
Study: NCT04478630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Description: Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Description: Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Description: Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
Study: NCT06096922

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04720131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg iv every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
Study: NCT04616547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tin Sn 117m Pentetate
Description: Given IV
Study: NCT05154578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 Vaccine
Description: 0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 Vaccine
Description: 0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline given by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline given by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline given by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline given by intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL normal saline given by intramuscular injection
Study: NCT05299138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marriage and Relationship Enhancement Skills (MRES) Intervention
Description: The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
Study: NCT05826041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.
Description: The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Domestic Violence Support Group
Description: The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
Study: NCT06417008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20117
Description: Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20117
Description: Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aumolertinib
Description: 110 mg orally once daily.